Pharmaceutical

TORL scores $158m in Series B2 to advance ADC cancer therapies

TORL plans to use the funds to advance the clinical development of its antibody-drug conjugate (ADC) pipeline.

Apr 11, 2024 - 00:00
TORL scores $158m in Series B2 to advance ADC cancer therapies
TORL plans to use the funds to advance the clinical development of its antibody-drug conjugate (ADC) pipeline.
Read the original article

Tags:

Previous Article

Lisata wins FDA orphan drug status for bone cancer candidate

Next Article

Acceleron Pharma gets grant for treatment of spinal muscular atrophy using ALK4:...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pandemic slowed cancer diagnoses, but late-stage cancers came back with a vengeance

Pandemic slowed cancer diagnoses, but late-stage cancer...

Aug 5, 2023

STAT+: New federal rules demand transparency into AI models used in health decisions

STAT+: New federal rules demand transparency into AI mo...

Dec 13, 2023

STAT+: Vertex’s closely watched pain relief drug succeeds in late-stage trials — with a catch

STAT+: Vertex’s closely watched pain relief drug succee...

Jan 30, 2024